Martin Münchbach

Martin Münchbach is a German businessman and entrepreneur who has been involved in the biotech and pharmaceutical industries for over two decades. Martin is currently the Director at Alentis Therapeutics, a position they have held since September 2020. Prior to this, they served as a Board Observer at Lava Therapeutics B.V from September 2020 to December 2021.

Münchbach began their career in the private equity industry, working as a Senior Investment Manager at Bellevue Asset Management from January 2004 to August 2021. Martin then transitioned into the biotech industry, co-founding Pureos Bioventures in 2006. Martin served as Managing Partner at the company until 2012, when they joined Binx Health as CEO. Martin led the company through its successful IPO in 2015 and remained CEO until 2018.

In 2019, Münchbach joined Ypsomed AG as Chief Executive Officer. Martin oversaw the company's successful expansion into the US market and its acquisition of River Renal Inc in 2020. Martin stepped down from their role as CEO in 2021 but remains on the Board of Directors.

Martin Münchbach has a Dr. rer. nat. ETHZ from ETH Zürich in Proteinchemistry, a MAS ETH MTEC from ETH Zürich in Management, Technology, and Economics, and a Dipl Natw. ETHZ from ETH Zürich in Biochemistry. Martin also has a degree in Biochemistry from the University of Tübingen.